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Summary
Extracellular signal-regulated kinase 1/2 (ERK1/2) signalling is a key pathway in cardiomyocyte hypertrophy and survival in response to
many different stress stimuli. We have previously characterized melusin as a muscle-specific chaperone protein capable of ERK1/2
signalling activation in the heart. Here, we show that in the heart, melusin forms a supramolecular complex with the proto-oncogene
c-Raf, MEK1/2 (also known as MAPKK1/2) and ERK1/2 and that melusin-bound mitogen-activated protein kinases (MAPKs) are
activated by pressure overload. Moreover, we demonstrate that both focal adhesion kinase (FAK) and IQ motif-containing GTPase
activating protein 1 (IQGAP1), a scaffold protein for the ERK1/2 signalling cascade, are part of the melusin complex and are required
for ERK1/2 activation in response to pressure overload. Finally, analysis of isolated neonatal cardiomyocytes indicates that both FAK
and IQGAP1 regulate melusin-dependent cardiomyocyte hypertrophy and survival through ERK1/2 activation.
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Introduction
Melusin is a muscle-specific protein belonging to the cysteine-
and histidine-rich domain (CHORD)-containing protein family
(Shirasu et al., 1999). Melusin, in fact contains two CHORD sites
in its N-terminal region, and a CS (CHORD-containing protein
and Sgt1) domain in its C-terminal moiety, a domain frequently
found in Hsp90 co-chaperones. We recently demonstrated that
melusin is able to bind Hsp90 chaperone protein and possesses
chaperone activity per se (Sbroggio` et al., 2008). Chaperones, as
well as assisting protein folding and thus preventing aggregation
and degradation, play an essential role in regulating signal
transduction pathways assisting conformational changes required
for protein activation (Pearl et al., 2008).
We have previously shown that melusin expression in the heart is
upregulated by mechanical stress induced by surgical banding of the
aorta (Sbroggio` et al., 2008), an intervention mimicking pathological
condition of pressure overload such as aortic stenosis and
hypertension. Forced melusin overexpression in the heart of
transgenic mice leads to cardiomyocyte hypertrophy and protects
from pressure overload-induced apoptosis, allowing the development
of sustained compensatory cardiac hypertrophy and preventing the
development of heart failure in conditions of long-standing pressure
overload (De Acetis et al., 2005). Melusin overexpression in the
mouse heart is able to strongly enhance ERK1/2 phosphorylation
both in basal conditions and in response to pressure overload stimuli
and this signalling pathway is required for melusin-induced
cardiomyocyte hypertrophy (De Acetis et al., 2005).
Here, we demonstrate that melusin forms a complex with the
mitogen-activated protein kinases (MAPKs), the proto-oncoprotein
c-Raf, MEK1/2 (also known as MAPKK1/2) and extracellular signal-
regulated kinase 1/2 (ERK1/2), the focal adhesion kinase (FAK) and
IQ motif-containing GTPase activating protein 1 (IQGAP1;
UniProtKB Q9JKF1), a MAPK scaffold protein. Moreover, using
pharmacological kinase inhibitors and null mice, we show that FAK
and IQGAP1 are required for melusin-dependent MAPK activation in
response to aortic banding, and play an important role in melusin-
induced cardiomyocyte hypertrophy and survival.
Results
Melusin enhances MAPK phosphorylation and interacts
with Raf, MEK1/2 and ERK1/2
As shown in Fig. 1A, and as previously demonstrated, melusin
overexpression in the heart of transgenic mice (melusin-TG)
enhances ERK phosphorylation, both in basal conditions and in
response to pressure overload induced by aortic banding (AB)
(De Acetis et al., 2005). This result led us to investigate the
possibility that melusin interacts with MAP kinases. Melusin was
immunoprecipitated from hearts of melusin-TG mice that were
subjected to AB or sham operation (basal conditions), and
analysed by western blotting, which revealed the presence of
c-Raf, MEK1/2 and ERK1/2 in the immunocomplex (Fig. 1B). In
agreement with our previous results (Sbroggio` et al., 2008), we
also detected the presence of Hsp90 (Fig. 1B). Interestingly, we
found that the amounts of melusin-associated MEK1/2 and
Hsp90 significantly increase in response to AB (Fig. 1B). The
specificity of the co-precipitation is demonstrated by the fact that
b-Raf, which is also expressed in the heart, was not detected in
association with melusin (Fig. 1B).
Melusin-bound MAPKs are activated by AB
To investigate if melusin-bound MAPKs are involved in signal
transduction triggered by AB, we subjected the immunoprecipitated
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samples to a kinase assay using recombinant ETS domain-
containing protein ELK1 as a substrate for ERK1/2. Western blot
analysis using anti-phosphorylated ELK1 antibodies demonstrated
that melusin-bound ERK1/2 are activated following AB (Fig. 1C).
Interestingly, the specific MEK1/2 inhibitors PD89059 (1 mM) and
U0126 (0.1 mM) were able to abolish the AB-dependent ERK1/2
activation, indicating the involvement of MEK1/2 as an upstream
kinase of ERK1/2 in this pathway (Fig. 1D and supplementary
material Fig. S1).
Identification of melusin binding partners
To investigate the mechanisms involved in the activation of melusin-
bound ERK1/2, we further analyzed melusin co-immunoprecipitated
material using both western blotting with phosphotyrosine
antibodies and mass spectrometry of Coomassie-Blue-stained
bands to identify possible additional signal transduction molecules.
As shown in Fig. 2A, a prominent 125 kDa band was clearly stained
when the melusin co-immunoprecipitated material was probed with
anti-phosphotyrosine antibodies. Using a panel of antibodies to
signalling molecules we identified this band as FAK, a well-known
kinase acting downstream of integrins and involved in ERK1/2
pathway activation (Fig. 2B). The amount of FAK associated with
melusin was not altered by AB (Fig. 2B).
When melusin co-immunoprecipitated proteins were analyzed
by Coomassie Blue staining, four major bands were detected with
molecular masses of 190 kDa, 84 kDa, 71 kDa and 52 kDa
(Fig. 2C). Matrix-assisted laser desoption/ionisation-time of flight
(MALDI-TOF) and liquid chromatography-nanospray-iontrap
tandem (LC-nanospray-IT) analysis identified the co-precipitated
band at 190 kDa as IQGAP1. IQGAP1 is a multidomain protein
that acts as a scaffold protein for the MAPK pathway by binding to
b-Raf (Ren et al., 2007), MEK1/2 and ERK1/2 (Roy et al., 2005),
and thus represents a potentially interesting molecule in the
complex. The other three additional bands are currently under
investigation and are not related to ERK signalling. MAPKs and
FAK were not detected in this assay, probably because of low
sensitivity of the Coomassie Blue staining. The amount of
IQGAP1 associated with melusin did not change after AB and
the interaction with this molecule was specific because KSR1 and
paxillin, two other proteins reported to act as scaffold for MAPKs,
were not present in the co-precipitated material (Fig. 2D).
IQGAP1 and FAK also co-immunoprecipitate with melusin from
wild-type heart, further strengthening the physiological relevance
of the interaction (Fig. 2E).
Because IQGAP1 has been originally described to bind several
small GTPases (Bashour et al., 1997; Awasthi et al., 2010), we
Fig. 1. Melusin-bound MAPKs are activated
by aortic banding. (A) Western blot analysis of
phosphorylated and total ERK1/2 in hearts from
wild-type (WT) and melusin-overexpressing
(MelTG) mice in basal condition (SH; sham
operated) and after 10 minutes of aortic banding
(AB). The graph shows densitometric
quantification of western blot bands (n56 mice/
group). (B) Immunoprecipitation of melusin from
MelTG hearts after AB for 10 minutes or sham
operation. Melusin-null hearts were used as
negative controls. Co-immunoprecipitated
proteins were visualized by western blot analysis.
Input: heart total protein extract loaded on the
same western blot as reference for molecular
masses. Quantification of the co-precipitated
proteins is shown in the graph (n510/group).
(C) ERK1/2 kinase assays were performed using
GST–ELK1 as a substrate on melusin
immunocomplexes obtained from MelTG hearts
after AB for 10 minutes or sham operation.
ERK1/2 kinase activity was revealed by western
blot analysis with anti-phosphorylated ELK1
(Ser338; n56/group). (D) ERK1/2 kinase assay
performed on melusin immunocomplex in
absence or presence of MEK1/2 inhibitor
PD89059 (1 mM; n53/group). *P,0.05;
***P,0.001; IP, immunoprecipitation;
KA, kinase assay.
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probed melusin immunoprecipitates with antibodies against Rac1,
Cdc42, Rap1 and Ras. As shown in supplementary material Fig. S2,
none of these proteins was detected in the complex.
FAK activity is required for ERK1/2 activation in melusin
complexes after AB
Previous works have described a role of FAK in ERK1/2
activation in several cell types (Guo and Giancotti, 2004; Mitra et
al., 2005; Vadali et al., 2007). We, therefore, investigated the
possibility that FAK has a role in melusin-associated ERK1/2
family MAPK activation in response to AB. As shown in Fig. 3A
and supplementary material Fig. S1, the FAK inhibitor PF573228
(0.1 mM) and inhibitor 14 (1 mM) abolished ELK1
phosphorylation in the ERK1/2 kinase assay, demonstrating
that melusin-associated ERK1/2 activation in response to AB
depends on FAK activity.
In agreement with these results, FAK kinase assays performed
on melusin immunocomplexes demonstrated that melusin-bound
FAK is activated by AB (Fig. 3B). In addition, direct
immunoprecipitation of FAK from heart extracts showed an
increased FAK kinase activity in response to AB (Fig. 3C), in
agreement with previous reports (Franchini et al., 2000).
IQGAP1 contributes to ERK1/2 activation in melusin
complexes after aortic banding.
Because IQGAP1 is a multidomain protein that acts as a scaffold
for the MAPK pathway by binding to b-Raf (Ren et al., 2007),
MEK1/2 and ERK1/2 (Roy et al., 2005), we investigated in
greater detail the possible role of IQGAP1 in melusin induced-
ERK1/2 activation. To this purpose we took advantage of
Iqgap1-null mice (Li et al., 2000; Bahou et al., 2004) and of
double transgenic mice overexpressing melusin in the heart in the
absence of IQGAP1 (melusin-TG/Iqgap1-null). Interestingly, we
noticed that absence of IQGAP1 abolished melusin-induced
ERK1/2 over-phophorylation both in basal conditions and in
response of aortic banding (supplementary material Fig. S3A).
Fig. 2. Melusin interacts with FAK and the MAPK scaffold
IQGAP1. (A) Western blot analysis of tyrosine phosphorylated proteins
in melusin immunocomplexes from MelTG hearts. (B) FAK co-
immunoprecipitation revealed by western blots of melusin
immunocomplexes isolated from MelTG hearts after AB for 10 minutes
or sham operation (n54 mice/group). Melusin-null hearts were used as
negative controls. (C) Coomassie Blue staining of melusin
immunoprecipitate from MelTG hearts. The indicated bands were cut
out and subjected to mass spectrometry analysis. (D) Western blot of
IQGAP1, KSR-1 and paxillin in melusin immunocomplexes isolated
from MelTG hearts after AB for 10 minutes or sham operation (n54
mice/group). (E) Western blot of IQGAP1 and FAK in melusin
immunoprecipitate from wild-type (WT) hearts after AB for 10 minutes
or sham operation (n54/group). Melusin-null hearts were used as
negative controls. Input: heart total protein extract.
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This finding led us to investigate whether IQGAP1 is required
for melusin–MAPK interaction. Co-immunoprecipitation of
melusin from double transgenic melusin-TG/Iqgap1-null hearts,
indicated that IQGAP1 is not required for melusin binding to
c-Raf, MEK1/2 or ERK1/2 (supplementary material Fig. S3B).
However, melusin is not required for IQGAP1 binding to
ERK1/2 family MAPKs, as shown by pull-down experiments
with IQGAP1 fragments (supplementary material Fig. S3C) from
wild-type and melusin-null hearts (supplementary material Fig.
S3D). Moreover, analysis of melusin and IQGAP1 binding
indicated a direct interaction through the CS domain of melusin
and the IQ domain of IQGAP1 (supplementary material Fig.
S3E–H). Thus, melusin and IQGAP1 can independently bind
ERK1/2 family MAPKs and can directly bind to each other.
To investigate the role of IQGAP1 in melusin-bound ERK1/2
activation in response to AB, we immunoprecipitated melusin
from melusin-TG and melusin-TG/Iqgap1-null mice hearts in
basal conditions and upon AB. We then subjected the
immunoprecipitated samples to an ERK1/2 kinase assay using
recombinant ELK1 as a substrate. As shown in Fig. 3D, the
absence of IQGAP1 clearly reduced ERK1/2 activity,
demonstrating that ERK1/2 activation in response to AB
depends on the presence of IQGAP1.
Melusin overexpression enhances ERK1/2
phosphorylation in cultured neonatal cardiomyocytes
through FAK and IQGAP1
Analysis of neonatal cardiomyocytes from melusin-TG mice
demonstrated that melusin overexpression induces significant
upregulation of ERK1/2 phosphorylation (Fig. 4A). We therefore
investigated the possibility that FAK activity is required for the
melusin-dependent MAPK phosphorylation in cardiomyocytes.
Wild-type and melusin-TG primary mouse cardiomyocytes were
treated with the FAK inhibitor PF573228 (3 mM) for 30 minutes,
and total protein extracts were then subjected to western blot
analysis with anti-phosphorylated ERK1/2. As shown in Fig. 4B,
both in wild-type and melusin-TG cardiomyocytes, FAK
inhibition reduced ERK1/2 phosphorylation to the same degree.
At the concentration used, PF573228 did not inhibit MEK1/2
activity as tested on MDA-MB-231 cells in which the ERK1/2
pathway is activated by constitutively active Ras (not shown).
This result indicates that increased ERK1/2 phosphorylation due
to melusin overexpression is dependent on FAK activity. The
efficacy of the inhibition was further confirmed by analyzing the
phosphorylation of tyrosine (Y) 397, a well-known
autophosphorylated residue on FAK (Fig. 4B).
Considering that MEK1/2 is the only known direct activator of
ERK1/2, our findings suggested that FAK is upstream of MEK1/
2. To investigate this we studied the effect of the FAK inhibitor
on MEK1/2 phosphorylation. As shown in Fig. 4B, melusin
overexpression increased MEK1/2 phosphorylation to a
comparable extent as that observed with ERK1/2. Notably, this
increased phosphorylation was abolished when cardiomyocytes
were treated with the FAK inhibitor PF573228 (Fig. 4B),
pointing to a causal relationship between FAK and MEK1/2.
To investigate the role of IQGAP1 in melusin-dependent ERK
phosphorylation we analyzed primary cardiomyocytes from wild-
type, melusin-TG and melusin-TG/Iqgap1-null mice. As shown
in Fig. 4C the enhancement in ERK1/2 phosphorylation due to
melusin overexpression is dependent on IQGAP1.
Fig. 3. Melusin-bound ERK1/2 activation requires FAK and IQGAP1. (A) ERK1/2 kinase assays performed on melusin immunocomplexes obtained from
MelTG hearts after AB for 10 minutes or sham operation, in the absence or presence of the FAK inhibitor PF573228 (0.1 mM). ERK1/2 kinase activity was
revealed by western blot analysis with anti-phosphorylated ELK1 (Ser338; n54/group). (B) FAK kinase assays performed on melusin immunocomplex obtained
from MelTG hearts after AB for 10 minutes or sham operation. FAK kinase activity was assayed using GST–FAK378–406 as a substrate, and revealed by western
blot analysis with anti-phosphorylated-FAK (Tyr397; n53/group). Melusin-null hearts were used as negative controls. (C) FAK kinase activity measured on FAK
immunocomplexes obtained from wild-type (WT) hearts after AB for 10 minutes or sham operation. FAK kinase activity was revealed by western blotting with
anti-phosphorylated-FAK (Tyr397; n54/group). (D) ERK1/2 kinase assay performed on melusin immunocomplex obtained from MelTG and MelTG/Iqgap1-null
(MelTG/IQ2/2) hearts after AB for 10 minutes or sham operation. ERK1/2 kinase activity was revealed by western blot analysis with anti-phosphorylated ELK1
(Ser338; n54/group). Melusin-null hearts were used as negative controls.
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FAK and IQGAP1 are required for melusin-induced
cardiomyocyte hypertrophy and survival
We previously demonstrated that melusin overexpression in
cardiomyocytes in vivo induces hypertrophy and protects against
apoptosis after long-standing AB (De Acetis et al., 2005).
Moreover, because the ERK1/2 pathway has been shown to be
involved in melusin-dependent cardiomyocyte hypertrophy (De
Acetis et al., 2005), we investigated the role of FAK and IQGAP1
in these phenomena using FAK inhibition and taking advantage
of melusin-TG/Iqgap1-null mice. In accordance with our
previous results, melusin-TG neonatal cardiomyocytes were
significantly larger than wild-type cells (Fig. 5A). We also
demonstrated that treatment of melusin-TG primary
cardiomyocytes with the FAK inhibitor PF573228 totally
abolished the melusin-dependent hypertrophy (Fig. 5A). Similar
to previous results (De Acetis et al., 2005), the MEK1/2 inhibitor
PD89059 also reversed the effect of melusin overexpression on
cell area (Fig. 5A). To exclude an unspecific effect of the FAK
inhibitor, we knocked down FAK in cardiomyocytes using a
lentivirus carrying a short hairpin RNA (shRNA) against FAK.
As shown in Fig. 5B, FAK expression was downregulated to 20%
of the level of control-infected cells, as quantified by
densitometry of the western blot bands. FAK knock-down in
melusin-TG cardiomyocytes reduced cell areas to the level of
Fig. 4. Melusin enhances ERK1/2 phosphorylation through FAK and IQGAP1. (A) Western blot analysis of phosphorylated and total ERK1/2 in neonatal
cardiomyocytes obtained from wild-type and MelTG mice. The graph shows the densitometric quantification of western blot bands (n55/group).
(B) Phosphorylation and total protein levels of MEK1/2, ERK1/2 and FAK measured by western blotting on wild-type and MelTG cardiomyocytes untreated or
treated with 3 mM PF573228. Anti-phosphorylated FAK (Tyr397), anti-phosphorylated MEK1/2 (Ser217/Ser221) and anti-phosphorylated ERK1/2 (Thr202/
Tyr204) were used. Densitometric quantification of western blot bands is shown in the graph (n54/group). (C) Western blot analysis of phosphorylated and total
ERK1/2 on neonatal cardiomyocytes obtained from wild-type, MelTG and MelTG/Iqgap1-null (MelTg/IQ2/2) mice. The graph shows the densitometric
quantification of western blot bands (n54/group). *P,0.05; **P,0.01; ***P,0.001.
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wild-type cardiomyocytes (Fig. 5C), confirming the results
obtained with the pharmacological inhibition of FAK.
Moreover, primary neonatal cardiomyocytes obtained from
melusin-TG/Iqgap1-null mice had a significantly reduced cell
area with respect to melusin-TG cardiomyocytes and comparable
with wild-type cells (Fig. 5D). Notably, neonatal cardiomyocytes
isolated from Iqgap1-null hearts had a cell area comparable with
that of wild-type cells (supplementary material Fig. S4A).
These results demonstrate that both FAK and IQGAP1 are
required for melusin-dependent hypertrophic effects on
cardiomyocytes. We thus decided to investigate the role of
FAK and IQGAP1 on melusin-dependent protection from
apoptosis (De Acetis et al., 2005). To this end wild-type and
melusin-TG neonatal cardiomyocytes were treated with H2O2
and apoptotic cells were detected with TUNEL assays. As shown
in Fig. 5E, melusin-TG cardiomyocytes showed a significantly
reduced number of apoptotic cells when treated with H2O2
compared with wild-type cardiomyocytes. Interestingly, both the
FAK inhibitor PF57322 and the MEK1/2 inhibitor PD89059 were
equally able to abolish the protective effect (Fig. 5E).
Furthermore, FAK knock-down abolished the melusin-mediated
protection from apoptosis, closely replicating the effects of FAK
pharmacological inhibition (Fig. 5F). Moreover, melusin-TG/
Iqgap1-null neonatal mouse cardiomyocytes had a significantly
higher mortality rate than melusin-TG cardiomyocytes, when
treated with H2O2 (Fig. 5G). The absence of IQGAP1 in wild-
type cardiomyocytes also resulted in increased apoptotic death in
response to oxidative stress (supplementary material Fig. S4B)
Fig. 5. FAK and IQGAP1 are required for melusin-induced cardiomyocyte hypertrophy and survival. (A) The effect of the FAK inhibitor PF573228 and
the MEK1/2 inhibitor PD89059 on cardiomyocyte surface areas, measured on at least 100 a-actinin-positive cells for each group (five cultures/group).
(B) Representative western blots of FAK protein levels in cardiomyocytes infected with lentivirus encoding Fak shRNA or control viruses. Vinculin was used as a
control for loading and RNA interference specificity. (C) Cardiomyocyte surface areas of cells treated as in B, measured on at least 100 a-actinin-positive, GFP-
positive cells for each group (four cultures/group). (D) Wild-type, MelTG and MelTG/Iqgap1-null cardiomyocyte surface areas measured on at least 100 a-
actinin-positive cells for each group (five cultures/group). (E) Percentage of apoptotic cardiomyocytes treated as in A, as indicated by TUNEL nuclear staining,
measured on at least 100 a-actinin-positive cells for each group (five cultures/group). (F) Percentage of apoptotic cardiomyocytes treated as in B and C, as
indicated by TUNEL nuclear staining and measured on at least 100 a-actinin-positive, GFP-positive cells for each group (4 cultures/group). (G) Percentage of
apoptotic cardiomyocytes after treatment with H2O2, as indicated by TUNEL nuclear staining, measured on at least 100 a-actinin-positive cells for each group
(five cultures/group). ***P,0.001; ˚˚˚P,0.001 versus untreated cells (NT).
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further demonstrating a role of IQGAP1 in cardiomyocyte
survival (Sbroggio` et al., 2011). These results demonstrated
that FAK and IQGAP1 act on the same melusin-activated signal
transduction pathway in promoting cell survival.
In conclusion, we have demonstrated that both FAK and
IQGAP1 are needed for the melusin-activated MAPK pathway
leading to hypertrophy and survival.
Discussion
Our previous findings demonstrated a key role of melusin in
triggering a compensatory hypertrophic program and in
preventing left ventricle dilation and heart failure in response
to long standing pressure overload. Melusin is a chaperone
molecule regulated by mechanical stress (Sbroggio` et al., 2008),
capable of activating AKT and ERK signalling, two pathways
required for melusin-induced cardiomyocyte hypertrophy and
survival (De Acetis et al., 2005). Here we show that melusin is
able to interact with the MAP kinases and it is part of a molecular
complex that includes the FAK, the scaffold protein IQGAP1 and
the chaperone protein Hsp90. FAK and IQGAP1 were identified
as key molecules in the complex responsible for ERK1/2
activation in response to pressure overload. To our knowledge
this is the first report describing a supramolecular complex
involved in the activation of the ERK1/2 cascade in hearts
challenged by pressure overload.
The MAPK pathway involves a cascade of three kinases (Raf,
MEK1/2 and ERK1/2) that sequentially activate each other by
phosphorylation. A key role in regulating such cascades is played
by scaffold proteins, which enhance signal efficiency by
assembling the molecules involved in signal transduction in
close proximity. IQGAP1 is a widely expressed multidomain
protein regulating different aspects of cell physiology and
capable of binding to distinct signalling molecules (Brown and
Sacks, 2006). Emerging evidence indicates that IQGAP1 acts as a
scaffold for the MAPK cascade by binding b-Raf, MEK1/2 and
ERK1/2, and regulating their activation in response to EGF in
fibroblasts and epithelial cells (Brown and Sacks, 2009). We
recently showed that IQGAP1 also acts as a scaffold of the
MAPK pathway in the heart by binding to c-Raf, MEK1/2 and
ERK1/2 (Sbroggio` et al., 2011). The role of IQGAP1 is
highlighted by the fact that in its absence, ERK1/2 activation is
impaired (see Fig. 3D), consistent with the property of scaffold
molecules to spatially organize the components of the MAPK
cascade.
Activation of ERK1/2 in response to AB is also dependent on
MEK1/2 and FAK kinase activities. In fact, FAK is also part of
the melusin complex, and specific inhibition of this kinase
abolished ERK1/2 activation in response to AB. FAK is a
ubiquitously expressed non-receptor tyrosine kinase acting as a
primary integrin effector at focal adhesion sites (Giancotti and
Ruoslahti, 1999; Parsons, 2003). Using kinase assays, we
demonstrated that melusin-bound FAK is activated in response
to AB, in agreement with previous findings (Franchini et al.,
2000). Several reports in the literature have indicated that FAK is
a crucial transducer for ERK1/2 activation downstream of
integrins and growth factor receptors (Guo and Giancotti, 2004;
Mitra et al., 2005; Vadali et al., 2007). The activation of ERK1/2
by FAK involves the recruitment of the adaptor protein Grb-2 to
the FAK C-terminal region, leading to the activation of the small
GTPase Ras through the guanosine exchange factor Sos. Ras,
however, was not detected in the melusin supramolecular
complex. Moreover, other GTPases known to be involved in
ERK1/2 signalling and to interact with IQGAP1, such as Rac1,
Cdc42 (Bashour et al., 1997) and Rap1 (Awasthi et al., 2010)
Fig. 6. Hypothetical model of the melusin supramolecular complex involved in ERK1/2 activation in cardiomyocytes. The protein complex indicated above
schematically illustrates the molecular interactions described in the results section. The model does not take into account the stoichiometry of the interactions and
it is not comprehensive of all possible interactions among the different protein in the complex. Chaperones are in blue, kinases are in orange and the scaffold
protein is in green. The stars indicate the activated state of the kinases.
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were not detectable in the complex, indicating that these GTPases
are not involved in FAK- and melusin-dependent ERK1/2
activation. Interestingly, however, our results demonstrated that
FAK activity is required for melusin-dependent MEK1/2
phosphorylation, indicating that FAK activates ERK1/2 through
MEK1/2. FAK-mediated and Ras-independent ERK1/2
activation has been reported in a number of experimental
systems (Chen et al., 1996; Hood et al., 2003; Slack-Davis et
al., 2003), but further studies are required to clarify the ability of
FAK to activate the MAPK pathway in a Ras-independent way.
Comparison of the supramolecular complexes isolated from
basal level and pressure-overloaded hearts indicated that the
amounts of FAK, IQGAP1, c-Raf and ERK1/2 were unaltered
following pressure overload. However, recruitment of MEK1/2 and
Hsp90 to the complex was significantly enhanced by pressure
overload. Because melusin binds Hsp90 and possesses chaperone
activity per se, we recently proposed a role for melusin as a co-
chaperone in the Hsp90 machinery (Sbroggio` et al., 2008). Hsp90 is
able to bind and protect a wide range of substrates or ‘client
proteins’ from degradation, and has a key role in signal transduction
because of its ability to maintain proteins in a three-dimensional
conformation that favours their activation (Pearl et al., 2008).
Therefore, a plausible hypothesis is that melusin, by interacting
with FAK, IQGAP1, c-Raf, MEK1/2 and ERK1/2 regulates the
MAPK pathway through its own chaperone activity and Hsp90
recruitment. In line with this hypothesis is the fact that FAK, c-Raf
and MEK1/2 are known Hsp90 client proteins (Schulte et al., 1997;
Sbroggio` et al., 2008). We hypothesize that the scaffold protein
IQGAP1 and the chaperone proteins melusin and Hsp90, are both
needed to fully activate the ERK1/2 pathway in response to
pressure overload in the heart. In fact, ERK1/2 activation requires
chaperones for stimulus-dependent conformational changes and
scaffold-mediated assembly of the three MAP kinases signalling
complex (Casar et al., 2009). An hypothetical model of the melusin
supramolecular complex is illustrated in Fig. 6.
Analysis of isolated cardiomyocytes from melusin-TG mice,
indicated that melusin-dependent ERK1/2 activation leads to
cardiomyocyte hypertrophy and protection from apoptosis in
response to stress stimuli, confirming and further extending our
previous data obtained from rat primary cardiomyocytes (De Acetis
et al., 2005). Moreover, FAK and IQGAP1, in addition to being
required for melusin-dependent ERK1/2 activation, are crucial in
melusin-induced cardiomyocyte hypertrophy and survival.
These findings on isolated cardiomyocytes are in agreement
with in vivo data obtained from transgenic mice. In fact, Fak-null
(DiMichele et al., 2006), melusin-null (unpublished data) and
Iqgap1-null mice (Sbroggio` et al., 2011) all show an impaired
wave of ERK1/2 phosphorylation in response to AB. Moreover,
absence of either FAK, melusin or IQGAP1 strongly impairs the
AB-induced cardiomyocyte hypertrophy, exacerbating cardiac
dysfunction in response to long-term AB (Brancaccio et al.,
2003; DiMichele et al., 2006; Sbroggio` et al., 2011).
Overall, these data underlie an important role of ERK1/2 in
adaptive cardiac remodelling (Kehat and Molkentin, 2010; Kehat
et al., 2011) and indicate a key role for melusin, FAK and
IQGAP1 in this pathway.
Materials and Methods
Mice
The use of animals was in compliance with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health and was
approved by the Animal Care and Use Committee of Turin University.
Mice were anesthetized with sodium pentothal (50 mg/kg, intraperitoneally)
and, after 20 minutes pressure overload was imposed to the left ventricle through
the surgical ligation of the abdominal aorta (aortic banding). After 10 minutes of
aortic banding, mice were sacrificed and hearts were collected. Sham-operated
animals underwent the same surgical procedures without aortic stenosis.
Cell culture
Cardiomyocytes were isolated from 1-day-old neonatal mice of the following types:
melusin-TG in the FVB genetic background, Iqgap1-null in the 129SV genetic
background and double transgenic melusin-TG/Iqgap1-null in the FVB/129SV
mixed background. Neonatal hearts were pre-digested overnight at 4 C˚ in Hank’s
balanced salt solution (HBSS) with 0.5 mg/ml trypsin (Sigma), followed by four
sequential dissociation cycles with 240 IU/ml collagenase type II (Worthington) in
HBSS. Fibroblasts were removed by two rounds of pre-plating for 2 hours on plastic
tissue culture dishes. Cardiomyocytes were plated on gelatin- and fibronectin-coated
dishes or glass coverslips and maintained in DMEM–M199 medium, 10% horse
serum (Gibco) and 5% FBS (Gibco). Final cultures contained .90%
cardiomyocytes as determined by immunofluorescence staining for sarcomeric a-
actinin (antibody from Sigma). When indicated, cells were treated with the inhibitor
PD890959 (50 mM; Calbiochem) or PF537228 (3 mM; Tocris) after 3 days in
culture. For western blot analyses of signalling pathways, cells were lysed for
30 minutes after treatment with inhibitors. For measurements of cell area, cells were
fixed after 2 days of treatment with the inhibitors. For analysis of apoptotic death
cells were treated with 1 mM H2O2 for 10 minutes and then cells were maintained in
normal culture medium in the absence or presence of inhibitors.
FAK knock-down was performed by infecting cardiomyocytes with pGIPZ
lentiviral particles expressing FAK shRNA together with green fluorescent protein
(GFP) reporter (Open Biosystems; clone ID V3LMM_440799) 24 hours after plating.
Empty pGIPZ lentiviral vector, expressing GFP reporter, was used as control. For
measurements of cell area and apoptosis, cells were fixed 4 days after infection.
Cardiomyocyte surface area and TUNEL assay
Neonatal cardiomyocytes were cultured on coverslips and maintained as described
above for 5 days after plating, and they were then fixed with 3% paraformaldheyde
(PFA) in PBS. To measure the surface area of cells, cells were treated with
immunofluorescent antibodies against a-actinin (sarcomeric) and phalloidin. Cell
areas were measured on images captured at 4006 magnification using Axio
Vision (Zeiss) software.
Cardiomyocyte apoptosis was assayed using the In Situ Cell Death Detection
Kit TMR red (Roche), following the manufacturer’s instructions. To ensure
exclusive counting of cardiomyocytes nuclei, cells were stained with anti-a-actinin
(sarcomeric) antibodies and nuclei were counterstained with DAPI. Cell area
measurements and apoptotic cell counts on FAK-knockdown cardiomyocytes were
only performed on a-scarcomeric-actinin- and GFP-positive cells, indicative of
lentivirus-infected cardiomyocytes.
Immunoprecipitations and western blotting
For immunoprecipitation experiments, hearts were homogenized in lysis buffer
(50 mM HEPES, 100 mM NaCl, 0.1% sodium deoxycholate, 0.1% Triton X-100,
1 mM EGTA, 2 mM EDTA), containing Roche complete protease inhibitor
cocktail, 10 mM NaF, 1 mM PMSF and 1 mM Na3VO4. Protein extracts were
clarified with three sequential centrifugations for 20 minutes at 20,000 g, at 4 C˚.
Immunoprecipitations were performed for 2 hours at 4 C˚ using 5 mg of total heart
proteins and 15 mg of anti-melusin (clone 5E1) (Sbroggio` et al., 2008) antibody,
covalently conjugated to CNBr–Sepharose beads (GE Healthcare). After
immunoprecipitation, beads were washed 10 times in lysis buffer and
resuspended in Laemmli buffer.
For western blotting, hearts were lysed in Tris-buffered saline with 1% Triton X-
100, plus phosphatase and protease inhibitors as indicated above. Neonatal
cardiomyocytes were lysed in RIPA buffer. Western blot band quantifications were
performed with Quantity One software (Bio-Rad).
For western blot analysis antibodies against the following proteins were used:
ERK1/2, MEK1/2, phospho-T202/Y204 ERK1/2, phospho-S217/S221 MEK1/2,
phospho-Y397 FAK, phospho-S338 ELK1, Ras, Cdc42 (Cell Signaling), IQGAP1,
Raf, b-Raf, p-Tyr (PY99), Rap1 (Santa Cruz), myc clone 9E10, vinculin (Sigma),
GST (Invitrogen), Hsp90 (Stressgene), KSR-1, paxillin, Rac1 (BD transduction),
FAK clone 2A7 (Millipore), and the mouse monoclonal anti-melusin 5E1
(Sbroggio` et al., 2008). A second monoclonal antibody against melusin (clone
C3) was produced in our laboratory by immunizing melusin-null mice with
recombinant GST–mouse melusin and its reactivity was characterized by western
blotting and immunoprecipitation. The epitope was mapped in the N-terminal
CHORD I–II region.
Kinase assays
The kinase activity of the melusin-bound ERK1/2 was detected by performing a
cold kinase assay, using recombinant GST–ELK1 (Cell Signaling) as the ERK1/2
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substrate, on the melusin immunoprecipitation as described above. Briefly,
immunoprecipitated samples were washed, the washing buffer was completely
removed and resuspended in 18 ml of kinase buffer (25 mM Tris-HCl pH 7.5,
5 mM b-glycerophosphate, 2 mM dithiothreitol, 1 mM Na3VO4, 10 mM MgCl2,
200 mM ATP) and 2 mg recombinant GST–ELK1. For FAK kinase assays, a GST
fusion recombinant protein containing a Y397 FAK autophorylation site (pGEX-
FAK amino acids 378–406) was used as a substrate (Chen and Chen, 2006).
Where indicated, samples were pre-incubated in kinase buffer plus 1 mM
PD890959 (Calbiochem), 0.1 mM PF537228, 0.1 mM U0126 or 1 mM FAK
inhibitor 14 (Tocris) for 10 minutes at room temperature, before the addition of
the substrate. Reactions were carried out at 30 C˚ for 30 minutes and stopped by
adding an equal volume of 26 Laemmli buffer, followed by 5 minutes
incubation at 95 C˚.
Mass spectrometry
Coomassie-Blue-stained pieces of gel were trypsin-digested and analyzed by
MALDI-TOF and LC-nanospray-IT mass spectrometry. MALDI mass spectra
were acquired on an Ultraflex II TOF-TOF instrument (Bruker Daltonics, Bremen,
Germany) equipped with a 200 Hz all-solid-state laser. LC-nanospray-IT
experiments were performed on a HP 1100 nanoLC system coupled to a XCT-
Plus nanospray-ion trap mass spectrometer (Agilent Italia). A database search
using the data from MALDI-TOF experiments was performed against the
UniProtKB/SwissProt-TrEMBL database using the Aldente search algorithm
(http://www.expasy.org/tools/aldente/); for nanoLC-nanospray-ion trap experi-
ments we used the NCBInr database and Mascot search algorithm (http://www.
matrixscience.com/search_form_select.html).
Recombinant proteins
Expression vectors encoding glutathione S-transferase (GST) and maltose binding
protein (MBP) fused to melusin were prepared as previously described (Sbroggio`
et al., 2008). To produce recombinant MBP-fused IQGAP1 fragments, the
nucleotide sequences encoding the protein fragments indicated in supplementary
material Fig S3C were cloned in pMAL C2 vector.
MBP and GST fusion proteins were produced in Escherichia coli BL21 bacterial
strain and purified as described below.
Pull-down assays
Frozen heart samples were homogenized with an Ultra-Turrax (VWR, West
Chester, PA) in Tris-buffered saline (TBS) plus 1% Triton X-100 with protease
and phosphatase inhibitors, centrifuged three times for 20 minutes at 20,000 g at
4 C˚, and ,3 mg total proteins were used for pull-down assays. MBP-fused
IQGAP1 and melusin fragments or MBP alone as control, were purified from
bacterial protein extracts using an amylose resin (GE Healthcare) for 1 hour at 4 C˚.
Resin was washed five times with TBS plus 1% Triton X-100, and 5 mg
recombinant protein was incubated (with agitation) with 3 mg of heart total
proteins for 2 hours. Resin was washed 10 times with TBS plus 1% Triton X-100
and resuspended in Laemmli buffer.
Pull-down experiments, to evaluate the direct interaction between melusin and
IQGAP1, were performed using MBP–IQGAP1 and GST–melusin fusion proteins,
together with MBP and GST alone as controls. Resin-bound proteins were washed
five times with interaction buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1%
Triton X-100) and only the GST fusion proteins were eluted from the resin with
10 mM glutathione. The purified proteins were then quantified using SDS-PAGE
and Coomassie Blue staining. Resin-bound MBP–IQGAP1 fragments and eluted
GST–melusin fragments (4 mmol of each) were incubated for 2 hours at 4 C˚ in
interaction buffer. Following incubation, resins were washed 10 times with
interaction buffer and resuspended in Laemmli buffer.
Statistical analyses
The data are presented as means ¡ s.e.m. Differences between experimental
groups were evaluated for statistical significance using one or two-way ANOVA
with Bonferroni’s correction. For all analyses, a minimum value of P,0.05 was
considered significant. All statistical analyses were performed using GraphPad
Prism 4 (GraphPad Software version 4.0).
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